详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma.

133| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine,Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East,Guangzhou, Guangdong 510060, P. R. China [2]Department of Radiation Oncology, Fujian Provincial Cancer Hospital, Fujian Medical University Department of Radiation Oncology, TeachingHospital of Fujian Medical University Provincial Clinical CollegeCancer Hospital of Fujian Medical University, Fuzhou, Fujian 350014, P. R. China [3]Department of Nasopharyngeal Carcinoma, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine,Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong510060, P. R. China [4]Department of Radiation Oncology, Cancer Center, West China HospitalSichuan University, Chengdu, Sichuan 610041, P. R. China [5]Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)Institute of Cancer and Basic Medicine (IBMC)ChineseAcademy of Sciences, Hangzhou, Zhejiang 310000, P. R. China [6]State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Medical Oncology Department, Sun Yat-SenUniversity Cancer Center, Guangzhou, Guangdong 510060, P. R. China [7]Department of Radiation Oncology, Sichuan Cancer Hospital and InstituteSichuan Cancer Center, School of Medicine, University of ElectronicScience and Technology of China, Chengdu, Sichuan 610041, P. R. China [8]Department of Radiation Oncology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui 230001, P. R. China [9]Department of Clinical Laboratory, Affiliated Cancer Hospital of Nanjing Medical UniversityJiangsu Cancer HospitalJiangsu Institute of CancerResearch, Nanjing, Jiangsu 210000, P. R. China [10]Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, P. R. China [11]Department of Radiotherapy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei430079, P. R. China [12]Department of Oncology, Tongji HospitalTongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei 430030, P. R.China [13]Department of Radiation Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, P. R. China [14]Department of Radiation Oncology, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi 541001, P. R. China [15]Key Laboratory of Basic Pharmacology and Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi MedicalUniversity, No. 6, Xuefu West Road, Xinpu New District, Zunyi, Guizhou 563000, P. R. China [16]Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Cancer Hospital & InstituteSchool ofMedicineUniversity of Electronic Science and Technology of China, Chengdu, Sichuan 610041, P. R. China [17]Department of Radiotherapy, Jiangxi Cancer Hospital, Nanchang, Jiangxi 330029, P. R. China [18]Department of Radiotherapy, Shaanxi Provincial Cancer Hospital Affiliated to Medical CollegeXi’an Jiaotong University, Xi’an, Shaanxi 710000, P. R.China [19]Department of Radiation Oncology, First Medical Center of Chinese PLA General Hospital, Beijing 100000, P. R. China [20]Department of Radiation Oncology, Yunnan Cancer HospitalThe Third Affiliated Hospital of Kunming Medical University, Kunming, Yunnan650100, P. R. China [21]Department of Radiation Oncology, Xiangya Hospital of Central South University, 87 Xiangya Road, Changsha, Hunan 410008, P. R. China [22]Department of Radiotherapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin300060, P. R. China [23]Department of Radiation Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530000, P. R. China [24]Department of Radiation Oncology, Key Laboratory of Oncology in Xinjiang Uyghur Autonomous Region, The Affiliated Tumor Hospital ofXinjiang Medical University, Urumqi, Xinjiang 830000, P. R. China [25]Department of Radiation Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital,Chongqing 400000, P. R. China [26]Department of Radiation Oncology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan 450000, P. R. China [27]Department of Radiotherapy, Peking University School of OncologyBeijing Cancer Hospital and Institute, Beijing, Haidian District 100142, P. R.China [28]Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P. R. China [29]Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy ofMedical Sciences and Peking Union Medical College, Beijing 100021, P. R. China [30]Department of Radiotherapy, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530000, P. R. China

出处：

DOI：

ISSN：

关键词： Chinese Society of Clinical Oncology CSCO Nasopharyngeal carcinoma Diagnosis Staging Risk Radiotherapy Chemotherapy Surgery Immunotherapy

摘要：

Nasopharyngeal carcinoma (NPC) is a malignant epithelial tumor originating in the nasopharynx and has a high incidence in Southeast Asia and North Africa. To develop these comprehensive guidelines for the diagnosis and management of NPC, the Chinese Society of Clinical Oncology (CSCO) arranged a multi-disciplinary team comprising of experts from all sub-specialties of NPC to write, discuss, and revise the guidelines. Based on the findings of evidence-based medicine in China and abroad, domestic experts have iteratively developed these guidelines to provide proper management of NPC. Overall, the guidelines describe the screening, clinical and pathological diagnosis, staging and risk assessment, therapies, and follow-up of NPC, which aim to improve the management of NPC.© 2021 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center.

语种：

高被引：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2023]版：

大类 | 1 区医学

小类 | 2 区肿瘤学

JCR分区：

出版当年[2021]版：

Q1 ONCOLOGY

最新[2023]版：

Q1 ONCOLOGY

影响因子： 20.1 最新[2023版] 16.7 最新五年平均 15.283 出版当年[2021版] 13.163 出版当年五年平均 10.392 出版前一年[2020版] 16.2 出版后一年[2022版]

第一作者：

第一作者机构： [1]Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine,Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East,Guangzhou, Guangdong 510060, P. R. China

通讯作者：

通讯机构： [1]Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine,Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East,Guangzhou, Guangdong 510060, P. R. China [*1]Department of Radiation Oncology, Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in SouthChina, Collaborative Innovation Centerof Cancer Medicine,Guangdong Key Laboratory of Nasopharyngeal CarcinomaDiagnosis and Therapy, 651 Dongfeng RoadEast, Guangzhou, Guangdong, 510060, P.R. China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma. $(function () { $("[data-toggle='tooltip']").tooltip(); });

文献详情

相关文献

The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma.